| Co-Investigator(Kenkyū-buntansha) |
MIURA Yutaka 東京農工大学, 大学院農学研究院, 教授 (10219595)
IZUMIKAWA Keiichi 東京農工大学, 大学院農学府, 特任助教 (60625713)
ISHIKAWA Hideaki 東京農工大学, 大学院農学府, 特任助教 (80625715)
YOSHIKAWA Harunori 東京農工大学, 大学院農学府, 特任助教 (60709567)
ISOBE Toshiaki 首都大学東京, 大学院理工学研究科, 特任教授 (70106607)
|
|---|
| Budget Amount *help |
¥43,030,000 (Direct Cost: ¥33,100,000、Indirect Cost: ¥9,930,000)
Fiscal Year 2015: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2014: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2013: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2012: ¥14,040,000 (Direct Cost: ¥10,800,000、Indirect Cost: ¥3,240,000)
|
|---|
| Outline of Final Research Achievements |
The cancer cells can grow indefinitely and quickly by increasing the efficiency of ribosome biogenesis that use the 60-80% of the energy and substances for which the cells are required. By inhibiting the action of a factor that increases the efficiency of the ribosome biogenesis in cancer cells, it is expected to suppress the proliferation of cancer cells. This study, based on the finding that LYAR is a such factor, has attempted to develop methods of screening for compounds that inhibit the action of LYAR. By analyzing the molecular mechanisms by which LYAR promote ribosome biogenesis, we identified a new factor that bind to LYAR without any co-factor between them. Unexpectedly, BRD4 was not the one that bind to directly to LYAR. It has become possible to develop a screening system of a new cancer treatment drugs based on the results.
|
